- Home
- CKPT vs CATX Comparison
CKPT vs CATX Comparison
Compare CKPT & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- CATX
- Stock Information
- Founded
- CKPT 2014
- CATX 1983
- Country
- CKPT United States
- CATX United States
- Employees
- CKPT N/A
- CATX N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- CKPT Health Care
- CATX Health Care
- Exchange
- CKPT Nasdaq
- CATX Nasdaq
- Market Cap
- CKPT 172.4M
- CATX 183.2M
- IPO Year
- CKPT 2017
- CATX N/A
- Fundamental
- Price
- CKPT $4.04
- CATX $1.94
- Analyst Decision
- CKPT Buy
- CATX Strong Buy
- Analyst Count
- CKPT 3
- CATX 11
- Target Price
- CKPT $4.33
- CATX $15.30
- AVG Volume (30 Days)
- CKPT 5.7M
- CATX 548.7K
- Earning Date
- CKPT 03-28-2025
- CATX 03-26-2025
- Dividend Yield
- CKPT N/A
- CATX N/A
- EPS Growth
- CKPT N/A
- CATX N/A
- EPS
- CKPT N/A
- CATX N/A
- Revenue
- CKPT $41,000.00
- CATX $1,454,000.00
- Revenue This Year
- CKPT $102,182.93
- CATX N/A
- Revenue Next Year
- CKPT $351.71
- CATX $1.15
- P/E Ratio
- CKPT N/A
- CATX N/A
- Revenue Growth
- CKPT N/A
- CATX 1.40
- 52 Week Low
- CKPT $1.38
- CATX $1.91
- 52 Week High
- CKPT $4.50
- CATX $19.10
- Technical
- Relative Strength Index (RSI)
- CKPT 65.90
- CATX 27.24
- Support Level
- CKPT $4.01
- CATX $2.32
- Resistance Level
- CKPT $4.07
- CATX $2.62
- Average True Range (ATR)
- CKPT 0.03
- CATX 0.19
- MACD
- CKPT -0.00
- CATX -0.02
- Stochastic Oscillator
- CKPT 70.00
- CATX 4.18
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.